Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observer-masked trial (Colour Bridge)

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515553-17-00

Acronym

RDC-CNGA3-01

Enrollment

Registered

2024-07-16

Start date

2021-03-11

Completion date

Unknown

Last updated

2025-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CNGA3-linked achromatopsia

Brief summary

Contrast sensitivity (Pelli Robson 3 m) 6 months after treatment

Detailed description

Contrast sensitivity (Pelli Robson 3 m), BCVA assessed using the ETDRS visual acuity protocol, FrACT (Freiburg Visual Acuity & Contrast Test), Roth FM28 sat, VA-CAL (Visual acuity under different conditions of contrast and ambient light), Patient reported outcomes (VFQ25/CVFQ, A3-PRO), Electroretinography, Chromatic pupil campimetry (CPC) cone protocol – exploratory - functional

Interventions

DRUGrAAV.hCNGA3

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Contrast sensitivity (Pelli Robson 3 m) 6 months after treatment	—

Secondary

Measure	Time frame
Contrast sensitivity (Pelli Robson 3 m), BCVA assessed using the ETDRS visual acuity protocol, FrACT (Freiburg Visual Acuity & Contrast Test), Roth FM28 sat, VA-CAL (Visual acuity under different conditions of contrast and ambient light), Patient reported outcomes (VFQ25/CVFQ, A3-PRO), Electroretinography, Chromatic pupil campimetry (CPC) cone protocol – exploratory - functional	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026